Silexion Therapeutics Announces 1-for-10 Reverse Share Split to Maintain Nasdaq Listing

On May 26, 2026, Silexion Therapeutics Corp (NASDAQ: SLXN) announced a 1-for-10 reverse share split of its ordinary shares, effective after the market close on May 28, 2026. Trading on a split-adjusted basis is scheduled to begin on the Nasdaq Capital Market at the open of the market on May 29, 2026. The split will automatically combine every ten existing shares into one new share, increasing the par value from $0.0135 to $0.135 per share. No fractional shares will be issued; instead, fractional entitlements for DTC participants will be rounded up to the nearest whole share. This strategic move is intended to regain compliance with Nasdaq's minimum bid price requirement and improve the company's capital structure. Additionally, Silexion highlighted that it expects to initiate a Phase 2/3 clinical trial of its lead siRNA candidate, SIL204, for locally advanced pancreatic cancer in the second quarter of 2026. The company believes the reverse split will reduce stock volatility and enhance flexibility for future equity financings to fund its clinical pipeline.